

## **Connecticut Department of Social Services Medical Assistance Program**

www.ctdssmap.com

Provider Bulletin 2018-21 April 2018

TO: Pharmacy Providers, Physicians, Nurse Practitioners, Physician Assistants, Long Term Care Providers, Clinics, and Hospitals

RE: Updated Cystic Fibrosis (CF) Prior Authorization Request Form for Orkambi, Kalvdeco and Symdeko

The purpose of this bulletin is to inform prescribing providers that effective May 1, 2018, Prior Authorization (PA) is required for prescription benefit coverage of Kalydeco and Symdeko for HUSKY A, HUSKY B, HUSKY C, and HUSKY D members.

Kalydeco (ivacaftor) is indicated for patients aged 2 and older who have one mutation in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene that is responsive to drug treatment based on clinical and/or in vitro (laboratory) data.

Symdeko (tezacaftor/ivacaftor) is indicated for the treatment of patients with CF aged 12 years and older, who are homozygous for the F508del mutation, which causes the production of an abnormal protein that disrupts how water and chloride are transported in the body, or who have at least one mutation in the CFTR gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence.

Effective May 1, 2018, the updated Cystic Fibrosis PA Request Form must be used to request a PA for Orkambi, Kalydeco and Symdeko. The updated form replaces the Orkambi PA request form currently being used for Orkambi.

The Cystic Fibrosis PA form is attached below and will be available on the www.ctdssmap.com Web site. From the Home

page, go to Information → Publications → Authorization/Certification Forms → Cystic Fibrosis PA Form; or Pharmacy Information → Pharmacy Program Publications → Cystic Fibrosis PA Form.



## STATE OF CONNECTICUT DEPARTMENT OF SOCIAL SERVICES TELEPHONE: 1-866-409-8386 FAX: 1-866-759-4110 OR (860) 269-2035

(This and other PA forms are posted on www.ctdssmap.com and can be accessed by clicking on the pharmacy icon)

## CT Medical Assistance Program CYSTIC FIBROSIS Prior Authorization (PA) Request Form [To be used for the authorization of Kalydeco, Orkambi and Symdeko]

Prescriber Information	Patient Inform	Patient Information		
Prescriber's NPI:	Patient's Medicaid ID Number:	Patient's Medicaid ID Number:		
Prescriber's Name:	Patient's Name:	Patient's Name:		
Prescriber's Phone # ( )	Patient's Date of Birth (MM/DD/CCYY):			
Prescriber's Fax # ( )				
Pr	escription Information			
Drug Requested:				
Quantity Requested:	Frequency of Dosing:			
Pharmacy's Fax: ( )				
Clin	<u>icalInformation</u>			
Kalydeco:				
Is the patient 2 years of age of older?		□ Yes	□ No	
Does the patient have a diagnosis of cystic fibrosis with one mutation in the CFTR gene that is responsive to ivacaftor based on clinical and/or in vitro assay data?		□ Yes	□ No	
Orkambi:	o assay data:			
Is the patient 6 years of age of older?		□ Yes	□ No	
Does the patient have a diagnosis of cystic fibrosis homozygous for the F508del mutation in the CFTR gene confirmed by an FDA-cleared CF mutation test?		□ Yes	□ No	
Symdeko:				
Is the patient 12 years of age of older?		□ Yes	□ No	
Does the patient have a diagnosis of cystic fibrosis homozygous for the F508del mutation in the CFTR gene confirmed by an FDA-cleared CF mutation test?		□ Yes	□ No	
f you answered "No" to any of the questions above, please Gen. Stat. § 17b-259b(a)) of this drug for this patient.	provide other information relating to the medic	al necessity (se	e Conn.	
certify that documentation is maintained in my files and the benalty under section 17b-99 of the Connecticut General Statute at the Agencies. I certify that the above-referenced memberior authorization may not exceed six (6) months from the con-controlled medications. Authorizations for Early Refill References	es and sections 17-83k-1- to 17-83k-7, inclusive, of er is a patient under my clinic's/practice's ong ne date of fill for controlled medications and one (	the Regulation oing care. I u	s of Connecticunderstand that	
Signature of Prescriber*	Date (MM/DD/CCYY)			

This form (and attachments) contains protected health information (PHI) for DXC Technology and is covered by the Electronic Communications Privacy Act, 18 U.S.C. § 2510-2521 and the Standards for Privacy of Individually Identifiable Health Information, 45 CFR Parts 160 and 164, which is intended only for the use of prior authorization. Any unintended recipient is hereby notified that the information is privileged and confidential, and any use, disclosure, or reproduction of this information is prohibited. Any unintended recipient should contact DXC Technology by telephone at (860) 255-3900 or by e-mail immediately and destroy the original message.

\* Mandatory (others may not sign for prescriber). In accordance with federal law, prescribers must be enrolled in the Connecticut Medical Assistance

Program (CMAP). CMAP will not pay for prescriptions written by a non-enrolled provider.